Upadacitinib 30mg modified-release tablets
NHS hospitals in England used £111,694,625 of indicative cost of Upadacitinib 30mg modified-release tablets in the 12 months to July 2026, about 0.4% of all hospital medicines spend. That is up 50.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Upadacitinib 30mg modified-release tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Upadacitinib 30mg modified-release tablets most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Salford Royal Nhs Foundation Trust | £3,291,992 |
| Barts Health Nhs Trust | £3,154,362 |
| Guy's & St Thomas' Nhs Foundation Trust | £3,142,784 |
| Oxford University Hospitals Nhs Ft | £2,752,689 |
| Univ Hpl B/Ham Nhs Foundation Trust | £2,700,235 |
| Univ Hpls Bristol Nhs Foundation Trust | £2,657,943 |
| King's College Hpl Nhs Foundation Trust | £2,442,912 |
| Gloucestershire Hpls Nhs Foundation Trst | £2,301,671 |
| Leeds Teaching Hpls Nhs Trust | £2,226,060 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £2,012,040 |
The primary-care picture
Upadacitinib is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Upadacitinib medicine page.